236 related articles for article (PubMed ID: 25883013)
1. Legius syndrome: case report and review of literature.
Benelli E; Bruno I; Belcaro C; Ventura A; Berti I
Ital J Pediatr; 2015 Feb; 41():8. PubMed ID: 25883013
[TBL] [Abstract][Full Text] [Related]
2. [A novel neurocutaneous syndrome: Legius syndrome. A case report].
Cemeli-Cano M; Peña-Segura JL; Fernando-Martínez R; Izquierdo-Álvarez S; Monge-Galindo L; López-Pisón J
Rev Neurol; 2014 Sep; 59(5):209-12. PubMed ID: 25156025
[TBL] [Abstract][Full Text] [Related]
3. Multiple café au lait spots in familial patients with MAP2K2 mutation.
Takenouchi T; Shimizu A; Torii C; Kosaki R; Takahashi T; Saya H; Kosaki K
Am J Med Genet A; 2014 Feb; 164A(2):392-6. PubMed ID: 24311457
[TBL] [Abstract][Full Text] [Related]
4. Legius syndrome: A case report.
Kimura R; Yoshida Y; Maruoka R; Kosaki K; Yamamoto O
J Dermatol; 2017 Apr; 44(4):459-460. PubMed ID: 28378438
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic and clinical significance of café-au-lait macules.
Shah KN
Pediatr Clin North Am; 2010 Oct; 57(5):1131-53. PubMed ID: 20888463
[TBL] [Abstract][Full Text] [Related]
6. Legius Syndrome and its Relationship with Neurofibromatosis Type 1.
Denayer E; Legius E
Acta Derm Venereol; 2020 Mar; 100(7):adv00093. PubMed ID: 32147744
[TBL] [Abstract][Full Text] [Related]
7. Family with Legius syndrome (neurofibromatosis type 1-like syndrome).
Sakai N; Maeda T; Kawakami H; Uchiyama M; Harada K; Tsuboi R; Mitsuhashi Y
J Dermatol; 2015 Jul; 42(7):703-5. PubMed ID: 25981987
[TBL] [Abstract][Full Text] [Related]
8. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
Bernier A; Larbrisseau A; Perreault S
Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
[TBL] [Abstract][Full Text] [Related]
9. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
10. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
[TBL] [Abstract][Full Text] [Related]
11. Halolike Phenomenon Around a Café au Lait Spot Superimposed on a Mongolian Spot.
Neri I; Lambertini M; Tengattini V; Rivalta B; Patrizi A
Pediatr Dermatol; 2017 May; 34(3):e152-e153. PubMed ID: 28523880
[TBL] [Abstract][Full Text] [Related]
12. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
13. Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?
Cassiman C; Casteels I; Jacob J; Plasschaert E; Brems H; Dubron K; Keer KV; Legius E
Clin Genet; 2017 Apr; 91(4):529-535. PubMed ID: 27716896
[TBL] [Abstract][Full Text] [Related]
14. Review and update of SPRED1 mutations causing Legius syndrome.
Brems H; Pasmant E; Van Minkelen R; Wimmer K; Upadhyaya M; Legius E; Messiaen L
Hum Mutat; 2012 Nov; 33(11):1538-46. PubMed ID: 22753041
[TBL] [Abstract][Full Text] [Related]
15. Moyamoya syndrome in a child with Legius syndrome: Introducing a cerebral vasculopathy to the SPRED1 phenotype?
Pabst L; Carroll J; Lo W; Truxal KV
Am J Med Genet A; 2021 Jan; 185(1):223-227. PubMed ID: 33078527
[TBL] [Abstract][Full Text] [Related]
16. A severe form of Noonan syndrome and autosomal dominant café-au-lait spots - evidence for different genetic origins.
Nyström AM; Ekvall S; Strömberg B; Holmström G; Thuresson AC; Annerén G; Bondeson ML
Acta Paediatr; 2009 Apr; 98(4):693-8. PubMed ID: 19120036
[TBL] [Abstract][Full Text] [Related]
17. Molecular screening strategies for NF1-like syndromes with café-au-lait macules (Review).
Zhang J; Li M; Yao Z
Mol Med Rep; 2016 Nov; 14(5):4023-4029. PubMed ID: 27666661
[TBL] [Abstract][Full Text] [Related]
18. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
[TBL] [Abstract][Full Text] [Related]
19. Café au lait spots: When and how to pursue their genetic origins.
Lalor L; Davies OMT; Basel D; Siegel DH
Clin Dermatol; 2020; 38(4):421-431. PubMed ID: 32972601
[TBL] [Abstract][Full Text] [Related]
20. Multiple café au lait macules and Crowe sign.
López Aventín D; Gilaberte M; Pujol RM
Arch Dermatol; 2011 Jun; 147(6):735-40. PubMed ID: 21690543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
